BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Bailey AJ, Maganti HB, Cheng W, Shorr R, Arianne Buchan C, Allan DS. Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis. Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/tp.0000000000004386] [Reference Citation Analysis]
2 Abdelmissih S. A Bitter Experience That Enlightens the Future: COVID-19 Neurological Affection and Perspectives on the Orexigenic System. Cureus 2022. [DOI: 10.7759/cureus.30788] [Reference Citation Analysis]
3 Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. BMC Med 2022;20:378. [PMID: 36199139 DOI: 10.1186/s12916-022-02587-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, Nakka K, Shir-mohammadi K, St-denis-bissonnette F, Tamblyn L, Vranjkovic A, Wood LC, Booth R, Buchan CA, Crawley AM, Little J, Mcguinty M, Saginur R, Langlois M, Cooper CL. Cohort profile: S top the Spread Ottawa (SSO) a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. BMJ Open 2022;12:e062187. [DOI: 10.1136/bmjopen-2022-062187] [Reference Citation Analysis]
5 Pellegrino R, Pellino G, Selvaggi L, Selvaggi F, Federico A, Romano M, Gravina AG. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study. Expert Rev Clin Pharmacol 2022. [PMID: 36047032 DOI: 10.1080/17512433.2022.2120466] [Reference Citation Analysis]
6 Sakuraba A, Luna A, Micic D. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses 2022;14:1822. [PMID: 36016444 DOI: 10.3390/v14081822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ge C, Du K, Luo M, Shen K, Zhou Y, Guo K, Liu Y, Yin C, Li Y, Li G, Chen X. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol 2022;11:46. [PMID: 35974381 DOI: 10.1186/s40164-022-00299-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jaewjaroenwattana J, Phoolcharoen W, Pasomsub E, Teengam P, Chailapakul O. Electrochemical paper-based antigen sensing platform using plant-derived monoclonal antibody for detecting SARS-CoV-2. Talanta 2022. [DOI: 10.1016/j.talanta.2022.123783] [Reference Citation Analysis]
9 Zeng H, Liu H, Liu Z, Zhou X, Lu X, Yan Z, Zhou Y, Dai L, Chen Y, Yang T, Yin Z, Ye Z. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study. Hum Vaccin Immunother 2022;:2090176. [PMID: 35878733 DOI: 10.1080/21645515.2022.2090176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Otten AT, Bourgonje AR, Horinga PP, van der Meulen HH, Festen EAM, van Dullemen HM, Weersma RK, van Leer-buter CC, Dijkstra G, Visschedijk MC. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Front Immunol 2022;13:920333. [DOI: 10.3389/fimmu.2022.920333] [Reference Citation Analysis]
11 Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022;71:1426-39. [PMID: 35477864 DOI: 10.1136/gutjnl-2021-326784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Makovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. Gut 2022:gutjnl-2022-327440. [PMID: 35606090 DOI: 10.1136/gutjnl-2022-327440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 See KC. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines 2022;10:800. [DOI: 10.3390/vaccines10050800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Antolí A, Rocamora-blanch G, Framil M, Mas-bosch V, Navarro S, Bermudez C, Martinez-yelamos S, Dopico E, Calatayud L, Garcia-muñoz N, Hernández-benítez LH, Riera-mestre A, Bas J, Masuet-aumatell C, Rigo-bonnin R, Morandeira F, Solanich X. Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. Front Immunol 2022;13:895209. [DOI: 10.3389/fimmu.2022.895209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, Sharma V. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(22)00210-9. [PMID: 35382972 DOI: 10.1016/j.dld.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Markovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG. Serological Responses to the First Three Doses of SARS-CoV-2 Vaccination in Inflammatory Bowel Disease: A Prospective Cohort Study.. [DOI: 10.1101/2022.03.16.22272440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022;13:1379. [PMID: 35296643 DOI: 10.1038/s41467-022-28517-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
18 Tang K, Wu X, Luo Y, Wei Z, Feng L, Wu L. Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Dayam RM, Law JC, Goetgebuer RL, Chao GYC, Abe KT, Sutton M, Finkelstein N, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Rymaszewski K, Milgrom R, Ganatra D, Batista NV, Girard M, Lau I, Law R, Cheung MW, Rathod B, Kitaygorodsky J, Samson R, Hu Q, Hardy WR, Haroon N, Inman RD, Piguet V, Chandran V, Silverberg MS, Gingras A, Watts TH. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases.. [DOI: 10.1101/2022.01.26.22269856] [Reference Citation Analysis]
20 Nishida Y, Hosomi S, Kobayashi Y, Nakata R, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Fujiwara Y. Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan. Healthcare (Basel) 2021;10:6. [PMID: 35052170 DOI: 10.3390/healthcare10010006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, Mcdonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones G, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T, Contributors of the CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients.. [DOI: 10.1101/2021.11.10.21266168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]